Rachel Xu

Rachel Xu

Senior Associate

Email rachel.xu@​hoganlovells.com

Phone +86 10 6582 9439

Fax +86 10 6582 9499

LanguagesEnglish, Mandarin

Practice groupGlobal Regulatory

After achieving her LL.M. degree at Columbia Law School, Rachel Xu joined the antitrust law practice in Hogan Lovells Washington D.C. Office. Through on-the-ground training in Washington D.C., one of the world's most competitive and high-profile antitrust law markets, she gained wide-range U.S. antitrust law experience including handling merger filing, conducting cartel investigation, providing antitrust counselling and representing clients in antitrust litigation.

Rachel is also active in U.S. and China legal/business community. She has assisted the Hogan Lovells D.C. Office hosting high-profile seminars and events facilitating and bridging communication between U.S. and China authorities, business and lawyers.

Prior to joining Hogan Lovells, Rachel worked at another leading international law firm for several years. Through her multi-area practice, she achieved comprehensive understanding of client's various needs in complex merger deals, internal investigations (antitrust/FCPA) and litigation/arbitration.

After relocation to Beijing, Rachel uses her skills assisting clients with Chinese and U.S. antitrust matters.

Education and admissions


LL.M., Columbia Law School, 2015

LL.B., Tsinghua University School of Law, 2010

Bar admissions and qualifications

New York

People's Republic of China

Representative experience

Conducted alleged price-fixing investigation for a U.S. company, in response to subpoena issued by U.S. competition authority.

Prepared U.S. HSR merger filing for a transaction between two U.S. leading plastic packaging manufacturers.

Assisted with the HSR merger filing for SABMiller's merger into Anheuser Busch InBev.

Conducted internal investigation for a Chinese company in response to proposed sanction by U.S. Department of Commerce regarding shipment to embargoed countries.

Advised a foreign company on a price fixing investigation by Chinese antitrust enforcement authorities after dawn raid at its office in Beijing.

Drafted merger control notification to MOFCOM for one of the world's largest pharmaceutical companies in its US$250 million acquisition in healthcare industry.

Drafted merger control filing with MOFCOM for it's the acquisition of a Chinese company by a world-leading IT corporation.

Loading data